COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
The effect of inhaled corticosteroids (ICS) on airway inflammation in chronic obstructive pulmonary disease (COPD)
Scientific title
A randomized controlled trial over 6 months to determine the effects of fluticasone propionate on lung function symptom scores, airway inflammation and airway structural remodelling in adult subjects with smoking related COPD
Secondary ID [1] 281402 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
chronic obstructive pulmonary disease (COPD) 287647 0
Condition category
Condition code
Respiratory 287977 287977 0 0
Chronic obstructive pulmonary disease

Study type
Description of intervention(s) / exposure
Inhaled fluticasone propionate versus placebo, 500mcg twice per day for 6 months
Intervention code [1] 285889 0
Treatment: Drugs
Comparator / control treatment
Lactulose powder (identical inhaler)
Control group

Primary outcome [1] 288194 0
Airway inflammatory cells and structural changes in bronchial biopsies from COPD patients before and after 6 months of treatment.
Airway inflammation was assessed by immuno-staining bronchial biopsies from COPD patients for different inflammatory markers. In recent work we are addressing structural changes in airways by looking at epithelial activation in COPD.
Timepoint [1] 288194 0
at 6 months
Secondary outcome [1] 299589 0
Clinical activity of COPD patients was assessed after 6 months on treatment.
Subjects completed a Quality of Life questionnaire (St Georges Respiratory Questionnaire, SGRQ) at baseline and following the treatment period. They also recorded daily symptoms of breathlessness, sputum expectoration, cough and salbutamol use in a diary card, during the run-in and throughout the treatment period. Symptom scores were averaged over 14 days and baseline values were compared with those at the end of treatment. All subjects returned for review every two months, at which time diary cards were checked, spirometry repeated, compliance with study medication checked and the subjects were asked about any exacerbations.
Timepoint [1] 299589 0
at 6 months

Key inclusion criteria
FEV1/FVC < 70% post bronchodilator and no other major co-morbidities
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Major confounding co-morbidities, steroids therapy in last 3 months

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?

Intervention assignment
Other design features
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment postcode(s) [1] 5843 0
Recruitment postcode(s) [2] 5844 0

Funding & Sponsors
Funding source category [1] 286159 0
Government body
Name [1] 286159 0
National Health and Medical Research Council (NHMRC)
Address [1] 286159 0
Level 1
16 Marcus Clarke Street
Canberra ACT 2601
Country [1] 286159 0
Funding source category [2] 286160 0
Commercial sector/Industry
Name [2] 286160 0
GlaxoSmithKline's (GSK)
Address [2] 286160 0
GlaxoSmithKline's (GSK)
Greenford, 980 Great West Road
Brentford, Middlesex,

United Kingdom
Country [2] 286160 0
United Kingdom
Primary sponsor type
Commercial sector/Industry
GlaxoSmithKline's (GSK)
GlaxoSmithKline's (GSK)
Greenford, 980 Great West Road
Brentford, Middlesex'

United Kingdom
United Kingdom
Secondary sponsor category [1] 284970 0
Name [1] 284970 0
Address [1] 284970 0
Country [1] 284970 0

Ethics approval
Ethics application status

Brief summary
The purpose of this study is to describe in better detail the airway inflammation and remodelling that we know occurs in COPD and to see what effect inhaled steroid medication has on the inflammation/structural changes and symptoms of the disease over a 6 month period.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 34839 0
Address 34839 0
Country 34839 0
Phone 34839 0
Fax 34839 0
Email 34839 0
Contact person for public queries
Name 18086 0
Professor E Haydn Walters
Address 18086 0
MS-1, 17 Liverpool Street, Private bag-23,
University of Tasmania, Hobart, TAS, 7000
Country 18086 0
Phone 18086 0
+61 3 6226-4870
Fax 18086 0
Email 18086 0
Contact person for scientific queries
Name 9014 0
Professor E Haydn Walters
Address 9014 0
MS-1, 17 Liverpool Street, Private bag-23,
University of Tasmania, Hobart, TAS, 7000
Country 9014 0
Phone 9014 0
+61 3 6226-4870
Fax 9014 0
Email 9014 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary